Terms: = Bone cancer AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Treatment
27 results:
1. Prevalence and Incidence of Fractures in Patients With Nonfunctional Adrenal Tumors.
Lindh JD; Patrova J; Mannheimer B; Falhammar H
JAMA Netw Open; 2024 Apr; 7(4):e246453. PubMed ID: 38619841
[TBL] [Abstract] [Full Text] [Related]
2. Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.
Gaumond SI; Abdin R; Costoya J; Schally AV; Jimenez JJ
Oncotarget; 2024 Apr; 15():248-254. PubMed ID: 38588464
[TBL] [Abstract] [Full Text] [Related]
3. bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate cancer Treated With Abiraterone Acetate.
Fukuokaya W; Mori K; Urabe F; Igarashi T; Yanagisawa T; Tsuzuki S; Honda M; Miki K; Kimura T
JAMA Netw Open; 2024 Mar; 7(3):e242467. PubMed ID: 38488793
[TBL] [Abstract] [Full Text] [Related]
4. Charcot neuroarthropathy in persons with diabetes: It's time for a paradigm shift in our thinking.
Wukich DK; Frykberg RG; Kavarthapu V
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3754. PubMed ID: 38069459
[TBL] [Abstract] [Full Text] [Related]
5. A cross-sectional study on Chinese oncology nurses' knowledge of bone health among cancer patients.
Shan J; Lv S; Chen L; Li T; Li J; Wang S; Zhang C
Support Care Cancer; 2023 Aug; 31(8):501. PubMed ID: 37526757
[TBL] [Abstract] [Full Text] [Related]
6. Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial.
Meduri B; Baldissera A; Iotti C; Scheijmans LJEE; Stam MR; Parisi S; Boersma LJ; Ammendolia I; Koiter E; Valli M; Scandolaro L; Busz D; Stenfert Kroese MC; Ciabatti S; Giacobazzi P; Ruggieri MP; Engelen A; Munafò T; Westenberg AH; Verhoeven K; Vicini R; D'Amico R; Lohr F; Bertoni F; Poortmans P; Frezza GP
J Clin Oncol; 2023 Apr; 41(12):2201-2210. PubMed ID: 36623246
[TBL] [Abstract] [Full Text] [Related]
7. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
[TBL] [Abstract] [Full Text] [Related]
8. Clinical Outcome Differences in the treatment of Impending Versus Completed Pathological Long-bone Fractures.
Groot OQ; Lans A; Twining PK; Bongers MER; Kapoor ND; Verlaan JJ; Newman ET; Raskin KA; Lozano-Calderon SA; Janssen SJ; Schwab JH
J Bone Joint Surg Am; 2022 Feb; 104(4):307-315. PubMed ID: 34851323
[TBL] [Abstract] [Full Text] [Related]
9. Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies.
Liu Y; Zhao S; Zhang Y; Onwuka JU; Zhang Q; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19835-19866. PubMed ID: 34375305
[TBL] [Abstract] [Full Text] [Related]
10. Secondary esophageal squamous cell carcinoma after hematopoietic stem cell transplantation.
Nomura K; Iizuka T; Kaji D; Asano-Mori Y; Ochiai Y; Suzuki Y; Hayasaka J; Yamashita S; Matsui A; Kikuchi D; Taniguchi S; Takazawa Y; Hoteya S
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2137-2144. PubMed ID: 33387042
[TBL] [Abstract] [Full Text] [Related]
11. Patterns of use of palliative radiotherapy fractionation for bone metastases and 30-day mortality.
Batumalai V; Descallar J; Delaney GP; Gabriel G; Wong K; Shafiq J; Vinod SK; Barton MB
Radiother Oncol; 2021 Jan; 154():299-305. PubMed ID: 33217497
[TBL] [Abstract] [Full Text] [Related]
12. [Synchronous multicentric osteosarcoma: treatment and prognostic factor analysis].
Liu WF; Huang Z; Gong LH; Yang YK; Jin T; Deng ZP; Li Y; Hao L; Zhang Q; Ding Y; Niu XH
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(37):2897-2902. PubMed ID: 31607017
[No Abstract] [Full Text] [Related]
13. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
[TBL] [Abstract] [Full Text] [Related]
14. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract] [Full Text] [Related]
15. Accuracy of CT Attenuation Measurement for Differentiating Treated Osteoblastic Metastases From Enostoses.
Elangovan SM; Sebro R
AJR Am J Roentgenol; 2018 Mar; 210(3):615-620. PubMed ID: 29323547
[TBL] [Abstract] [Full Text] [Related]
16. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract] [Full Text] [Related]
17. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study.
Zhao H; Li L; Su H; Lin B; Zhang X; Xue S; Fei Z; Zhao L; Pan Q; Jin X; Xie C
Oncotarget; 2016 Oct; 7(43):70969-70978. PubMed ID: 27391158
[TBL] [Abstract] [Full Text] [Related]
18. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.
Terada N; Akamatsu S; Okada Y; Negoro H; Kobayashi T; Yamasaki T; Matsui Y; Inoue T; Kamba T; Ogawa O
Int J Clin Oncol; 2016 Dec; 21(6):1155-1161. PubMed ID: 27351872
[TBL] [Abstract] [Full Text] [Related]
19. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract] [Full Text] [Related]
20. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Brufsky AM; Harker WG; Beck JT; Bosserman L; Vogel C; Seidler C; Jin L; Warsi G; Argonza-Aviles E; Hohneker J; Ericson SG; Perez EA
Cancer; 2012 Mar; 118(5):1192-201. PubMed ID: 21987386
[TBL] [Abstract] [Full Text] [Related]
[Next]
